Protective Antibody Level After COVID-19 Vaccination Among Patients Under Hemodialysis
NCT ID: NCT04871945
Last Updated: 2022-03-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
31 participants
OBSERVATIONAL
2021-04-20
2021-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Antibody Response in Hemodialysis and Non-dialysis Patients Diagnosed With COVID-19.
NCT04633915
Response of Haemodialysis Patients to BNT162b2 mRNA Cov-19 Vaccine
NCT04881396
COVADIAL - Immunogenicity of COVID-19 Vaccine in Hemodialysis Patients
NCT04728828
The Immune System in End Stage CKD Patients - Comparison Among Different Modalities of RRT
NCT04286477
Safety and Efficacy of the Coronavirus Disease 2019 Vaccine in Hemodialysis Patients
NCT04944433
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Elecsys Anti-SARS-CoV-2 S (Roche Diagnostics GmbH, Mannheim, Germany), 2) ACCESS SARS-CoV-2 IgG II (Beckman Coulter, Inc. USA)
The antibody level will be measured by the above mentioned methods. The trial drugs are not used but the vaccine that included in National Immunization Program for COVID-19 in Korea will be used for the study.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The person who agrees with the protocol of the study
Exclusion Criteria
* Pregnants
* Experience of COVID-19 infection
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Seegene Medical Foundation
UNKNOWN
Hanyang University Seoul Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hanyang University Seoul Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Park JS, Minn D, Hong S, Jeong S, Kim S, Lee CH, Kim B. Immunogenicity of COVID-19 Vaccination in Patients With End-Stage Renal Disease Undergoing Maintenance Hemodialysis: The Efficacy of a Mix-and-Match Strategy. J Korean Med Sci. 2022 Jun 13;37(23):e180. doi: 10.3346/jkms.2022.37.e180.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-02-033
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.